{"id":"bgb-dxp593","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4209157","moleculeType":"Small molecule","molecularWeight":"478.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD73 is a key enzyme involved in the production of adenosine, which plays a role in tumor immune evasion. By inhibiting CD73, BGB-DXP593 aims to reduce adenosine levels and enhance anti-tumor immune responses.","oneSentence":"BGB-DXP593 is a small molecule inhibitor targeting the CD73 enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:29.060Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"}]},"trialDetails":[{"nctId":"NCT04669262","phase":"PHASE1","title":"BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-12-09","conditions":"Healthy","enrollment":25},{"nctId":"NCT04551898","phase":"PHASE2","title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-12-02","conditions":"Covid19","enrollment":181},{"nctId":"NCT04532294","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-09-08","conditions":"Covid19","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BGB-DXP593","genericName":"BGB-DXP593","companyName":"BeiGene","companyId":"beigene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BGB-DXP593 is a small molecule inhibitor targeting the CD73 enzyme. Used for Solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}